GlassScriptPhysician profile
Gowri Balachandar
NPI 1669435889
$4,220.35
in general payments reported to CMS, 2019-2025
27 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $323 · 2021: $462 · 2022: $778 · 2023: $466 · 2024: $908 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,130 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.73 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $975.99 | 2019-2025 | Mavyret |
| Vivus LLC | $561.77 | 2020-2025 | Qsymia, Pancreaze |
| Pfizer INC. | $459.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.74 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.37 | 2019-2025 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $215.42 | 2019-2024 | Suflave |
| Ardelyx, INC. | $205.92 | 2022-2025 | Ibsrela |
| Evoke Pharma, INC. | $186.92 | 2021-2025 | Gimoti |
| Lilly USA, LLC | $152.23 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $151.21 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $113.22 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Madrigal Pharmaceuticals | $94.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $89.44 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $82.44 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $63.88 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $59.60 | 2020-2022 | |
| Gilead Sciences, INC. | $47.23 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $39.91 | 2020-2021 | |
| Genzyme Corporation | $39.51 | 2025 | |
| Intra-Sana Laboratories | $36.32 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Redhill Biopharma INC. | $29.68 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.70 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $17.31 | 2019 | |
| Alfasigma USA, INC. | $16.53 | 2021 | |
| Endo Pharmaceuticals INC. | $14.22 | 2019 | |
| Shire North American Group INC | $12.99 | 2019 | |
| Daiichi Sankyo INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gowri Balachandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.